Browsing by Author "Spino, Cathie"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Open Access FSGS Recurrence Collaboration: Report of a Symposium.(Glomerular diseases, 2024-01) Gipson, Debbie S; Wang, Chia-Shi; Salmon, Eloise; Gbadegesin, Rasheed; Naik, Abhijit; Sanna-Cherchi, Simone; Fornoni, Alessia; Kretzler, Matthias; Merscher, Sandra; Hoover, Paul; Kidwell, Kelley; Saleem, Moin; Riella, Leonardo; Holzman, Lawrence; Jackson, Annette; Olabisi, Opeyemi; Cravedi, Paolo; Freedman, Benjamin Solomon; Himmelfarb, Jonathan; Vivarelli, Marina; Harder, Jennifer; Klein, Jon; Burke, George; Rheault, Michelle; Spino, Cathie; Desmond, Hailey E; Trachtman, HowardItem Open Access Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today.(Kidney international, 2024-02) Trachtman, Howard; Desmond, Hailey; Williams, Amanda L; Mariani, Laura H; Eddy, Sean; Ju, Wenjun; Barisoni, Laura; Ascani, Heather K; Uhlmann, Wendy R; Spino, Cathie; Holzman, Lawrence B; Sedor, John R; Gadegbeku, Crystal; Subramanian, Lalita; Lienczewski, Chrysta C; Manieri, Tina; Roberts, Scott J; Gipson, Debbie S; Kretzler, Matthias; NEPTUNE investigatorsGlomerular diseases are classified using a descriptive taxonomy that is not reflective of the heterogeneous underlying molecular drivers. This limits not only diagnostic and therapeutic patient management, but also impacts clinical trials evaluating targeted interventions. The Nephrotic Syndrome Study Network (NEPTUNE) is poised to address these challenges. The study has enrolled >850 pediatric and adult patients with proteinuric glomerular diseases who have contributed to deep clinical, histologic, genetic, and molecular profiles linked to long-term outcomes. The NEPTUNE Knowledge Network, comprising combined, multiscalar data sets, captures each participant's molecular disease processes at the time of kidney biopsy. In this editorial, we describe the design and implementation of NEPTUNE Match, which bridges a basic science discovery pipeline with targeted clinical trials. Noninvasive biomarkers have been developed for real-time pathway analyses. A Molecular Nephrology Board reviews the pathway maps together with clinical, laboratory, and histopathologic data assembled for each patient to compile a Match report that estimates the fit between the specific molecular disease pathway(s) identified in an individual patient and proposed clinical trials. The NEPTUNE Match report is communicated using established protocols to the patient and the attending nephrologist for use in their selection of available clinical trials. NEPTUNE Match represents the first application of precision medicine in nephrology with the aim of developing targeted therapies and providing the right medication for each patient with primary glomerular disease.